Claims (12)
1. Antitijelo humanog monoklonskog anti-interleukina-17F (IL-17F), ili njegov fragment koji veže antigen, naznačen time, da antitijelo prepoznaje konformacijski epitop na IL-17F i sposobno je neutralizirati biološku aktivnost IL-17F, i antitijelo ili njegov fragment koji veže antigen sadržavaju u svom varijabilnom teškom lancu (VH) i varijabilnom lakom lancu (VH) aminokiselinsku sekvencu VH i VL lanca SEQ ID NO: 15 odnosno 17, ili SEQ ID NO: 23 i 25, redom.1. Human monoclonal anti-interleukin-17F (IL-17F) antibody, or its antigen-binding fragment, characterized in that the antibody recognizes a conformational epitope on IL-17F and is capable of neutralizing the biological activity of IL-17F, and the antibody or its fragment which bind antigen contain in their variable heavy chain (VH) and variable light chain (VH) the amino acid sequence of the VH and VL chain SEQ ID NO: 15 and 17, respectively, or SEQ ID NO: 23 and 25, respectively.
2. Antitijelo ili fragment koji veže antigen u skladu s patentnim zahtjevom 1, naznačen time, da je to Fv fragment jednog lanca (scFv), F (ab ') fragment, F (ab) fragment ili F (ab')2 fragment.2. An antibody or antigen-binding fragment according to claim 1, characterized in that it is an Fv fragment of a single chain (scFv), an F (ab') fragment, an F (ab) fragment or an F (ab')2 fragment.
3. Antitijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da sadržava konstantnu regiju CH i / ili CL koja sadržava sekvencu aminokiselina odabranu iz CH i CL aminokiselinskih sekvenci prikazanih u SEQ ID NO: 11, 13, 19, 21, 27, i 29 ili aminokiselinska sekvenca s najmanje 60% identiteta.3. Antibody according to patent claim 1 or 2, characterized in that it contains a constant region CH and/or CL which contains an amino acid sequence selected from the CH and CL amino acid sequences shown in SEQ ID NO: 11, 13, 19, 21, 27 , and 29 or an amino acid sequence with at least 60% identity.
4. Jedan ili više polinukleotida, naznačen time, da kodiraju barem varijabilno područje antitijela ili fragmenta koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3.4. One or more polynucleotides, characterized in that they encode at least the variable region of an antibody or an antigen-binding fragment according to any one of claims 1 to 3.
5. Jedan ili više vektora, naznačen time, da sadržavaju polinukleotid (e) iz zahtjeva 4.5. One or more vectors, characterized by the fact that they contain polynucleotide (e) from claim 4.
6. Stanica domaćin, naznačena time, da sadržava polinukleotid ili polinukleotide u skladu s patentnim zahtjevom 4 ili vektor (i) u skladu s patentnim zahtjevom 5.6. The host cell, characterized in that it contains a polynucleotide or polynucleotides in accordance with claim 4 or a vector (i) in accordance with claim 5.
7. Antitijelo ili fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je detektabilno obilježen ili vezan za lijek.7. An antibody or antigen-binding fragment according to any one of claims 1 to 3, characterized in that it is detectably labeled or bound to a drug.
8. Antitijelo ili fragment koji veže antigen, naznačen time, da se detektabilna oznaka odabire iz skupine koja se sastoji od enzima, radioizotopa, fluorofora i teškog metala.8. An antibody or fragment that binds an antigen, characterized in that the detectable label is selected from the group consisting of an enzyme, a radioisotope, a fluorophore and a heavy metal.
9. Pripravak, naznačen time, da sadržava antitijelo ili fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3, 7 ili 8, polinukleotid ili polinukleotide u skladu s patentnim zahtjevom 4, vektor ili vektore u skladu s patentnim zahtjevom 5 ili stanica u skladu s patentnim zahtjevom 6, poželjno pri čemu pripravak sadržava dva protutijela koja u svom VH lancu i VL lancu sadrže aminokiselinske sekvence VH i VL lanca od SEQ ID NO: 15 i 17, odnosno SEQ ID NO: 23 i 25, redom.9. Preparation characterized in that it contains an antibody or an antigen-binding fragment according to any one of claims 1 to 3, 7 or 8, a polynucleotide or polynucleotides according to claim 4, a vector or vectors according to claim 5 or a cell according to patent claim 6, preferably wherein the preparation contains two antibodies which in their VH chain and VL chain contain the amino acid sequences of the VH and VL chain of SEQ ID NO: 15 and 17, respectively SEQ ID NO: 23 and 25, respectively .
10. Pripravak u skladu s patentnim zahtjevom 9, naznačen time, da je:
(a) farmaceutski pripravak i nadalje sadržava farmaceutski prihvatljiv nosač, poželjno nadalje sadržava dodatni agens koristan za liječenje upale ili autoimunog poremećaja, odabranog iz skupine koja se sastoji od nesteroidnih protuupalnih lijekova (NSAID), kortikosteroida, antihistamina i njihove kombinacije, ili
(b) dijagnostički pripravak ili komplet i nadalje sadržava reagense za upotrebu u dijagnostičkim metodama na temelju imuno- ili nukleinske kiseline.10. Preparation according to patent claim 9, characterized in that:
(a) the pharmaceutical composition and further contains a pharmaceutically acceptable carrier, preferably further containing an additional agent useful for the treatment of inflammation or an autoimmune disorder, selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antihistamines and combinations thereof, or
(b) a diagnostic preparation or kit further comprising reagents for use in immuno- or nucleic acid-based diagnostic methods.
11. Antitijelo ili fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3,7 ili 8, naznačen time, da se koristi za liječenje ili prevenciju napredovanja upale ili autoimunog poremećaja; za ublažavanje simptoma povezanih s upalom ili autoimunim poremećajem; za dijagnosticiranje ili probir subjekta na prisutnost ili za određivanje rizika subjekta za razvoj upale ili autoimunog poremećaja, poželjno pri čemu su spomenuto antitijelo ili fragment koji veže antigen dizajnirani da se daju intravenski, intramuskularno, subkutano, intraperitonealno, intranazalno, parenteralno ili kao aerosol.11. An antibody or fragment that binds an antigen according to any one of patent claims 1 to 3, 7 or 8, indicated that it is used for the treatment or prevention of the progression of inflammation or an autoimmune disorder; to relieve symptoms associated with inflammation or an autoimmune disorder; for diagnosing or screening a subject for the presence of or for determining a subject's risk for developing inflammation or an autoimmune disorder, preferably wherein said antibody or antigen-binding fragment is designed to be administered intravenously, intramuscularly, subcutaneously, intraperitoneally, intranasally, parenterally or as an aerosol.
12. Antitijelo ili fragment koji se veže za antigen, namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time, da je navedeni poremećaj odabran iz skupine koju čine acne vulgaris; artritis, kao što je artritis iz gihta, sistemski eritematozni lupus (SLE), osteoartritis, psorijatični artritis, reumatoidni artritis; astma; celijakija; kronični prostatitis; dermatitis; dijabetes melitus Ttp 1; glomerulonefritis; preosjetljivosti; miokarditis; multipla skleroza; upalne bolesti crijeva; upalna bolest zdjelice; polimiozitis; psorijaza; sarkoidoza; vaskulitis; intersticijalni cistitis ili upale koje nastaju zbog reperfuzijske ozljede ili odbacivanja transplantata.12. An antibody or fragment that binds to an antigen, intended for use in accordance with claim 11, characterized in that said disorder is selected from the group consisting of acne vulgaris; arthritis, such as gouty arthritis, systemic lupus erythematosus (SLE), osteoarthritis, psoriatic arthritis, rheumatoid arthritis; asthma; celiac disease; chronic prostatitis; dermatitis; diabetes mellitus Ttp 1; glomerulonephritis; hypersensitivity; myocarditis; multiple sclerosis; inflammatory bowel diseases; pelvic inflammatory disease; polymyositis; psoriasis; sarcoidosis; vasculitis; interstitial cystitis or inflammation resulting from reperfusion injury or graft rejection.